Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Breast Neoplasms 22Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Endometrioid Endometrial Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Diseases 1Breast Carcinoma In Situ 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Unresectable or Metastatic Breast Cancer of Adults 1Advanced Solid Tumor 1

Interventions

exemestane 1Leuprolide 1Letrozole 1Goserelin 1Gonadotropin-Releasing Hormone 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sexual Dysfunctions, Psychological × Letrozole × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡